Archives of microbiologySep 26, 2025

Overview of new methods to fight antibiotic resistance

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

No new class of antibiotics has been developed in the past decade despite rising challenges from antimicrobial resistance (AMR).

AMR is increasingly diminishing the effectiveness of many first-line antibiotics due to overuse and misuse.
Recent strategies to combat AMR include the use of antimicrobial peptides, phage therapy, and CRISPR-Cas gene editing.
Innovative tactics such as nanomaterial-based antimicrobials and immunomodulatory agents are being explored as alternatives to traditional antibiotics.
There is a shift towards integrated next-generation therapeutics that combine various approaches to address drug-resistant pathogens.
Collaboration among researchers, healthcare professionals, policymakers, and the pharmaceutical sector is essential to tackle the AMR crisis.

Simplified

Antimicrobial Resistance (AMR) is a growing global issue, as many first-line antibiotics are becoming less effective due to their overuse and misuse. Recent advances in novel antibiotic derivatives reveal mechanisms designed to counteract AMR. Even though conventional antimicrobial therapy has failed, no new antibiotic class has been developed in the past decade. Consequently, various innovative alternative tactics have been discovered to counteract drug-resistant pathogens. The article reviews novel approaches in combating AMR, which include antimicrobial peptides, phage therapy, CRISPR-Cas gene editing, nanomaterial-based antimicrobials, immunomodulatory agents, innovative physicochemical strategies, and combination therapy. Collectively, these approaches utilize cutting edge technologies that mark a shift from the traditional paradigm of antibiotics to integrated next-generation therapeutics. AMR remains a serious issue despite all of the noted advancements, and hence, a collaborative and multidisciplinary action involving researchers, healthcare professionals, policymakers, and pharmaceutical sector is urgently required. The emergence and burden of AMR can be better tackled by inventiveness, cooperation, and proactive approaches.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declarations. Conflict of interest: The authors declare no competing interests. Research involving human participants and/or animals: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: Not Applicable.

PubMed

Overview of new methods to fight antibiotic resistance

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief